Navigating 11 Analyst Ratings For Bicycle Therapeutics
Portfolio Pulse from Benzinga Insights
Bicycle Therapeutics (NASDAQ:BCYC) has received mixed analyst ratings, with a majority being bullish. The average 12-month price target is $41.82, slightly down from the previous $43.00. The company faces revenue challenges but maintains strong financial metrics like net margin and ROE.
October 24, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bicycle Therapeutics has received mixed analyst ratings, with 7 out of 11 being bullish. The average price target is $41.82, slightly lower than the previous $43.00. The company faces revenue challenges but maintains strong financial metrics.
The mixed analyst ratings indicate a neutral short-term impact on BCYC's stock price. While the majority of analysts are bullish, the slight decrease in the average price target and revenue challenges suggest caution. However, strong financial metrics like net margin and ROE provide a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100